Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GelStat Corporation (GSAC)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
3557 SW Corporate Parkway 34990
Palm City, FL, US
Palm City, FL, US
CEO
Javier G. Acosta
Website
gelstat.com
IPO
1996-02-09
CIK 890725 ISIN US3685331056
Description
GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) and other non-prescription health solutions. Its diverse product portfolio addresses various common health concerns, featuring: GelStat Migraine, a patented remedy targeting migraine headache pain; Chews 2 Lose, an appetite-controlling gum designed to assist with weight management; All Natural Speed, formulated as an energy booster; and GelStat Sleep, intended to alleviate sleep disturbances and their related symptoms. GelStat distributes its solutions through a comprehensive network, reaching retailers, wholesalers, specialized distributors, and catalog merchandisers. This is achieved both through direct sales and via independent sales brokerage agreements. The corporation maintains its principal office in Palm City, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.72
Float Shares
530.21M
Free Float %
85.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -14.29% | -25.00% | -25.00% | -14.29% | -25.00% | -66.67% | -97.39% | -91.67% | -99.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-94.76
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+133.9% ★ Q2'25: +2.8% (vs Q2'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+50.0% ★
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-107.7% Q2'25: -19.3% (vs Q2'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-80.4% Q2'25: -87.0% (vs Q2'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'25: +65.9% (vs Q2'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+130.6% Q2'25: +2.5% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.65× Q2'25: -3.42× (vs Q2'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-14.7K
OE per share TTM
0.00
Owner's Yield
-1.57%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
17.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
4.00
Bullish
Buys
4
Sells
1
Shares acquired
87.05M
Shares disposed
—
Cash buys
4.00
Cash sales
—
Net activity
+87,053,209
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-04 | Goldfarb Adrian Graham | Director | P-Purchase | A | Common Stock, par value $0.01 | 53,209,459 | 0.01 | 319.3K | 87,768,609 | — | ↗ |
| 2022-02-04 | Acosta Javier G | Director / Officer | — | D | Common Shares | 0 | 0.00 | — | 50,000,000 | — | ↗ |
| 2020-11-30 | Goldfarb Adrian Graham | Director | J-Other | D | Common Stock, par value $0.01 | 280,400 | 0.00 | — | 715,400 | — | ↗ |
| 2015-03-04 | Goldfarb Adrian Graham | Director | J-Other | D | Common Stock, par value $0.01 | 719,600 | 0.00 | — | 995,800 | — | ↗ |
| 2012-12-31 | Goldfarb Adrian Graham | Director | J-Other | D | Common Stock, par value $0.01 | 2,052,600 | 0.00 | — | 1,715,400 | — | ↗ |
| 2010-05-03 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.03 | 330.00 | 8,157,428 | — | ↗ |
| 2010-04-30 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 50,000 | 0.03 | 1.6K | 8,147,428 | — | ↗ |
| 2010-04-08 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.03 | 290.00 | 5,597,428 | — | ↗ |
| 2010-04-06 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 0.03 | 580.00 | 5,587,428 | — | ↗ |
| 2010-04-05 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 0.03 | 580.00 | 5,567,428 | — | ↗ |
| 2010-04-01 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.03 | 290.00 | 5,547,428 | — | ↗ |
| 2010-03-31 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.03 | 290.00 | 5,537,428 | — | ↗ |
| 2010-03-30 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.03 | 290.00 | 5,527,428 | — | ↗ |
| 2010-03-29 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 40,700 | 0.02 | 895.40 | 5,517,428 | — | ↗ |
| 2010-03-26 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.03 | 300.00 | 5,476,728 | — | ↗ |
| 2010-03-25 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 0.02 | 475.00 | 5,466,728 | — | ↗ |
| 2010-03-15 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | D | Warrants | 500,000 | 0.01 | 6.0K | 2,550,000 | — | ↗ |
| 2010-03-10 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 1,375 | 0.02 | 22.00 | 5,441,728 | — | ↗ |
| 2010-03-08 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 18,625 | 0.01 | 223.50 | 5,440,353 | — | ↗ |
| 2009-12-30 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 50,000 | 0.01 | 550.00 | 5,421,728 | — | ↗ |
| 2009-12-28 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.01 | 150.00 | 5,371,728 | — | ↗ |
| 2009-12-16 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 30,000 | 0.01 | 360.00 | 5,356,728 | — | ↗ |
| 2009-11-19 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 0.01 | 65.00 | 5,326,728 | — | ↗ |
| 2009-11-09 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 3,521 | 0.01 | 49.29 | 5,321,728 | — | ↗ |
| 2009-11-03 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 0.01 | 300.00 | 5,318,207 | — | ↗ |
| 2009-10-30 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 50 | 0.13 | 6.55 | 5,293,207 | — | ↗ |
| 2009-10-28 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 900 | 0.02 | 17.10 | 5,293,157 | — | ↗ |
| 2009-10-27 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 9,900 | 0.01 | 128.70 | 5,292,257 | — | ↗ |
| 2009-09-14 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 4,500 | 0.01 | 49.50 | 5,282,357 | — | ↗ |
| 2009-08-31 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 6,129 | 0.01 | 67.42 | 5,277,857 | — | ↗ |
| 2009-07-15 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 11,600 | 0.01 | 139.20 | 5,271,728 | — | ↗ |
| 2009-06-25 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 8,400 | 0.02 | 184.80 | 5,260,128 | — | ↗ |
| 2009-06-10 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.02 | 270.00 | 5,251,728 | — | ↗ |
| 2009-06-05 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | D | Common Stock | 73,500 | 0.01 | 830.55 | 5,236,728 | — | ↗ |
| 2009-05-28 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.01 | 150.00 | 5,310,228 | — | ↗ |
| 2009-04-20 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 4,500 | 0.00 | 15.75 | 5,295,228 | — | ↗ |
| 2009-04-17 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 4,000 | 0.00 | 14.00 | 5,290,728 | — | ↗ |
| 2009-04-14 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.00 | 40.00 | 5,286,728 | — | ↗ |
| 2009-03-10 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 24,500 | 0.01 | 269.50 | 5,186,728 | — | ↗ |
| 2009-03-05 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 500 | 0.01 | 5.50 | 5,162,228 | — | ↗ |
| 2009-02-20 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 0.03 | 125.00 | 5,161,728 | — | ↗ |
| 2009-02-04 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 0.02 | 80.00 | 5,156,728 | — | ↗ |
| 2009-01-30 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 0.03 | 160.00 | 5,151,728 | — | ↗ |
| 2009-01-26 | Kieft Gerald N II | Officer / 10% Owner | P-Purchase | A | Common Stock | 9,000 | 0.02 | 180.00 | 5,146,728 | — | ↗ |
| 2009-01-23 | Kieft Gerald N II | Officer | P-Purchase | A | Common Stock | 51,000 | 0.02 | 1.1K | 5,137,728 | — | ↗ |
| 2009-01-21 | Kieft Gerald N II | Officer | P-Purchase | A | Common Stock | 11,000 | 0.04 | 385.00 | 5,086,728 | — | ↗ |
| 2009-01-20 | Kieft Gerald N II | Officer | P-Purchase | A | Common Stock | 55,000 | 0.03 | 1.6K | 5,075,728 | — | ↗ |
| 2008-10-29 | Goldfarb Ronnie Sue | Officer | — | I | Common Stock | 0 | 0.00 | — | 1,016,000 | — | ↗ |
| 2008-10-19 | Kieft Gerald N II | Officer | P-Purchase | A | Common Stock | 175,000 | 0.03 | 5.3K | 5,020,728 | — | ↗ |
| 2008-10-19 | Goldfarb Adrian Graham | Director | P-Purchase | A | Common Stock | 175,000 | 0.03 | 5.3K | 3,768,000 | — | ↗ |
| 2008-09-26 | Kieft Gerald N II | Officer | — | I | Common Stock | 0 | 0.00 | — | 2,750,000 | — | ↗ |
| 2008-09-26 | Goldfarb Adrian Graham | Director | — | D | Common Stock | 0 | 0.00 | — | 1,000 | — | ↗ |
| 2007-04-27 | COLUCCI WILLIAM R | Director | — | D | Common Stock | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2007-03-07 | Kieft Gerald N II | Officer | — | D | Warrants | 50,000 | 0.25 | 12.5K | 0 | — | ↗ |
| 2006-11-13 | RINGOLD RICHARD W | Director / Officer | A-Award | A | Non-qualified Stock Options (right to buy) | 250,000 | 0.06 | 15.0K | 250,000 | — | ↗ |
| 2006-11-13 | LaFlamme James Bryant | Director | A-Award | A | Non-qualified Stock Options (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2006-11-13 | Chavanu Michael John | Director | A-Award | A | Non-qualified Stock Options (right to buy) | 250,000 | 0.06 | 15.0K | 250,000 | — | ↗ |
| 2006-10-07 | LaFlamme James Bryant | Director | — | D | Options (right to buy) | 50,000 | 0.11 | 5.5K | 0 | — | ↗ |
| 2006-10-07 | Chavanu Michael John | Director | — | D | Options (right to buy) | 50,000 | 0.11 | 5.5K | 0 | — | ↗ |
| 2006-08-09 | RINGOLD RICHARD W | Director / Officer | A-Award | A | Options (right to buy) | 420,000 | 0.07 | 29.4K | 420,000 | — | ↗ |
| 2006-07-12 | LaFlamme James Bryant | Director | — | D | Warrants (right to buy) | 70,000 | 0.20 | 14.0K | 0 | — | ↗ |
| 2006-07-12 | Chavanu Michael John | Director | — | D | Warrants (right to buy) | 38,888 | 0.20 | 7.8K | 0 | — | ↗ |
| 2006-06-23 | LaFlamme James Bryant | Director | — | D | Common Stock | 0 | 0.00 | — | 180,000 | — | ↗ |
| 2006-06-15 | Chavanu Michael John | Director | — | D | Common Stock | 0 | 0.00 | — | 401,388 | — | ↗ |
| 2006-01-04 | RINGOLD RICHARD W | Director / Officer | G-Gift | A | Common Stock | 140,000 | 0.00 | — | 240,000 | — | ↗ |
| 2005-12-03 | ROBERTS STEPHEN CHARLES | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-11-16 | ROBERTS STEPHEN CHARLES | Director / Officer | A-Award | A | Options (right to buy) | 660,000 | 0.30 | 198.0K | 660,000 | — | ↗ |
| 2005-11-16 | RINGOLD RICHARD W | Director / Officer | A-Award | A | Options (right to buy) | 520,000 | 0.30 | 156.0K | 520,000 | — | ↗ |
| 2005-11-16 | MILLER DONALD | Director / Officer | A-Award | A | Options (right to buy) | 100,000 | 0.30 | 30.0K | 100,000 | — | ↗ |
| 2005-11-16 | EHLEN K JAMES | Director | A-Award | A | Options (right to buy) | 50,000 | 0.30 | 15.0K | 50,000 | — | ↗ |
| 2005-05-27 | RINGOLD RICHARD W | Director / Officer | G-Gift | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2005-04-29 | EHLEN K JAMES | Director | P-Purchase | A | Common Stock | 10,000 | 1.40 | 14.0K | 25,000 | — | ↗ |
| 2005-04-26 | ROBERTS STEPHEN CHARLES | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.92 | 9.2K | 1,427,179 | — | ↗ |
| 2005-02-02 | MILLER DONALD | Director | A-Award | A | Warrant (right to buy) | 13,000 | 1.00 | 13.0K | 13,000 | — | ↗ |
| 2005-01-01 | BLUHM NICHOLAS C | Officer | — | D | Options (right to buy) | 600,000 | 3.37 | 2.02M | 0 | — | ↗ |
| 2004-12-14 | MILLER DONALD | Director | A-Award | A | Warrant (Right to buy) | 17,000 | 3.00 | 51.0K | 17,000 | — | ↗ |
| 2004-09-27 | EHLEN K JAMES | Director | — | D | GelStat Common Stock | 0 | 0.00 | — | 15,000 | — | ↗ |
| 2004-08-12 | MILLER DONALD | Director | — | D | GelStat Common Stock | 0 | 0.00 | — | 150,000 | — | ↗ |
| 2004-07-22 | LOWENTHAL GARRY N | Officer | — | D | Options | 120,000 | 2.75 | 330.0K | 0 | — | ↗ |
| 2004-07-09 | RINGOLD RICHARD W | Director / Officer | — | D | Options | 120,000 | 2.75 | 330.0K | 0 | — | ↗ |
| 2004-07-01 | RINGOLD RICHARD W | Director / Officer | A-Award | A | Options (right to buy) | 270,000 | 3.37 | 909.9K | 270,000 | — | ↗ |
| 2004-07-01 | BLUHM NICHOLAS C | Officer | — | D | GelStat Common Stock | 0 | 0.00 | — | 14,400 | — | ↗ |
| 2003-12-29 | RINGOLD RICHARD W | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-09-01 | LOWENTHAL GARRY N | Officer | — | D | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-08-01 | RINGOLD RICHARD W | Director / Officer | — | D | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-140.5K
Shares Outstanding
617.98M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Charles F. Tarzian | Chief Marketing Advisor | — | male |
| Javier G. Acosta | Chief Executive Officer & Director | — | male |
| Roger K. Cady | Chief Medical Advisor | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GSAC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
